Evidence map›Paper›PMID 34998606›Full record

ArticleVaccine2022

Protection against avian coronavirus conferred by oral vaccination with live bacteria secreting LTB-fused viral proteins.

Avishai Lublin, Chen Katz, Nady Gruzdev, Itamar Yadid, Itai Bloch, Yigal Farnoushi, Luba Simanov, Asaf Berkowitz, Dalia Elyahu, Jacob Pitcovski and 1 more

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Incorporation ofBiosafety and health · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Avishai LublinThe Department of Avian Diseases, Kimron Veterinary Institute, Israel.
Chen KatzMIGAL Research Institute in the Galilee, Kiryat Shmona, Israel.
Nady GruzdevMIGAL Research Institute in the Galilee, Kiryat Shmona, Israel.
Itamar YadidMIGAL Research Institute in the Galilee, Kiryat Shmona, Israel; Tel-Hai Academic College, Upper Galilee, Israel.
Itai BlochMIGAL Research Institute in the Galilee, Kiryat Shmona, Israel.
Yigal FarnoushiThe Department of Avian Diseases, Kimron Veterinary Institute, Israel.
Luba SimanovThe Department of Avian Diseases, Kimron Veterinary Institute, Israel.
Asaf BerkowitzThe Department of Avian Diseases, Kimron Veterinary Institute, Israel.
Dalia ElyahuMIGAL Research Institute in the Galilee, Kiryat Shmona, Israel.
Jacob PitcovskiMIGAL Research Institute in the Galilee, Kiryat Shmona, Israel; Tel-Hai Academic College, Upper Galilee, Israel.
Ehud ShaharMIGAL Research Institute in the Galilee, Kiryat Shmona, Israel; Tel-Hai Academic College, Upper Galilee, Israel. Electronic address: Ehudsha@migal.org.il.
Migal - Galilee Technology Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The devastating impact of infectious bronchitis (IB) triggered by the IB virus (IBV), on poultry farms is generally curbed by livestock vaccination with live attenuated or inactivated vaccines. Yet, this approach is challenged by continuously emerging variants and by time limitations of vaccine preparation techniques. This work describes the design and evaluation of an anti-IBV vaccine comprised of E. coli expressing and secreting viral spike 1 subunit (S1) and nucleocapsid N-terminus and C-terminus polypeptides fused to heat-labile enterotoxin B (LTB) (LS1, LNN, LNC, respectively). Following chicken oral vaccination, anti-IBV IgY levels and cellular-mediated immunity as well as protection against virulent IBV challenge, were evaluated 14 days following the booster dose. Oral vaccination induced IgY levels that exceeded those measured following vaccination with each component separately. Following exposure to inactivated IBV, splenocytes isolated from chicks orally vaccinated with LNN or LNC -expressing bacteria, showed a higher percentage of CD8

Indexed as

Coronavirus InfectionsGammacoronavirusInfectious bronchitis virusPoultry DiseasesViral VaccinesAnimalsAntibodies, ViralChickensEscherichia coliVaccinationVaccines, AttenuatedViral ProteinsAntibodies, ViralVaccines, AttenuatedViral ProteinsViral VaccinesAvian corona virusFusion polypeptidesHeat labile enterotoxinInfectious bronchitis virusOral vaccinationSubunit vaccine

Identifiers

PMID34998606
PMCPMC8717763
OpenAlexW4225646217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.